Key result
DOACs match or reduce thromboembolic and bleeding events versus VKAs in cancer patients with AF.
Why the study?
Balancing clotting and bleeding risks is challenging in cancer patients with AF, and half do not receive any oral anticoagulation.
Do DOACs improve thromboembolic and bleeding outcomes compared to VKAs in cancer patients with atrial fibrillation?
Systematic Review
Do DOACs improve thromboembolic and bleeding outcomes compared to VKAs in cancer patients with atrial fibrillation?
DOACs may be preferable to VKAs for thromboembolic prophylaxis in cancer patients with non-valvular AF due to similar or better efficacy and safety profiles and fewer drug interactions.
Answers are grounded in this paper and cite their sources.
Supports preferring DOACs over VKAs in cancer-associated AF; extends limited evidence but low-certainty data leave optimal use open.
A relationship between malignancy and impaired hemostasis has been proven, and balancing clotting and bleeding risks can be challenging. Half of cancer patients with atrial fibrillation (AF) do not receive any oral anticoagulation (OAC). Using PubMed on the relationship between cancer and AF and their association with hemostasis, targeting studies comparing vitamin K antagonists (VKAs) and direct OAC (DOAC) strategies in AF cancer patients, three RCTs (>3000 patients) and eight observational studies (>250,000 patients) comparing different OACs were retrieved. The VKA prescribed was always warfarin. Dabigatran was the only DOAC not analyzed in the RCTs but the most used in non-randomized studies, whereas edoxaban-treated patients were the majority in the RCTs. Overall, the DOAC patients showed similar or lower rates of efficacy (thromboembolic) and safety (bleeding) outcomes compared to the VKA patients. DOACs are subject to fewer interactions with antineoplastic agents. DOACs may be preferable to VKAs as a thromboembolic prophylaxis in cancer patients with non-valvular AF.
No takes yet. Share an insight, caveat, or question.
Franchina et al. (2023) conducted a systematic review in Cancer with atrial fibrillation. Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated on Thromboembolic and bleeding outcomes. Direct oral anticoagulants showed similar or lower rates of thromboembolic and bleeding outcomes compared to vitamin K antagonists in cancer patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: